Autoimmune approvals, AI infrastructure hardens
The cure wire stayed dense today: 21,295 active trials, 34 new signals, and 31 new research items in 24 hours. On the clinical side, AbbVie won European Commission approval for RINVOQ in severe alopecia areata and non-segmental vitiligo, while Novartis secured FDA traditional approval for Fabhalta in primary IgAN. At the same time, the AI layer beneath discovery kept consolidating, with model controls, fresh funding, and new infrastructure signaling that more biological search is being routed through software. Progress remains uneven, but the center of gravity is still moving toward more treatable disease. The window is still open.
AbbVie received European Commission approval for RINVOQ for severe alopecia areata and non-segmental vitiligo, while Novartis received FDA traditional approval for Fabhalta in primary IgAN.
These approvals expand the set of diseases with sanctioned therapies, giving patients and companies immediate access while showing that immune and kidney disease remain active fronts in the cure race.
Watch whether recent AI control shifts and capital flows accelerate the biology stack, and whether the newly approved therapies translate into broader real-world reach before the next regulatory and research cycle closes.